New Roadmap Outlines Strategies to Accelerate Drug Development for Pediatric Chronic Kidney Disease

An international, multidisciplinary collaboration of nephrologists, pharmacologists, biostatisticians, regulatory experts, industry representatives, and patient advocates has published a comprehensive roadmap to address the scarcity of treatments for pediatric chronic kidney disease (CKD). Published in Nature Health Sciences, the new framework outlines urgent therapeutic needs, summarizes current landscape constraints, and addresses clinical trial challenges in this underserved patient group. Paediatric CKD remains a progressive, life-altering condition linked to significant comorbidities, reduced life expectancy, and substantial burdens on families and health care systems.

While adult nephrology has experienced major therapeutic breakthroughs, similar drug developments for children remain exceptionally sparse. Approvals for medicines designed to slow CKD progression in pediatric patients continue to be limited to specific underlying kidney conditions. Furthermore, standard trial endpoints used in adults—such as the glomerular filtration rate slope—face notable limitations when applied to children, though emerging evidence suggests that tracking changes in proteinuria could serve as a viable surrogate endpoint for specific glomerular diseases.

To overcome these hurdles, the roadmap highlights several strategic necessities, including strengthening surrogate endpoint qualification, adopting adaptive and innovative clinical trial methodologies, leveraging real-world data, and fostering coordinated global efforts. Researchers emphasize that these steps are critical for accelerating therapeutic innovation and addressing unmet medical needs in pediatric populations. Readers should consult a qualified medical professional for any personal health, diagnostic, or treatment decisions.

What to know: A new expert roadmap highlights the lack of treatments for children with chronic kidney disease and calls for innovative clinical trial designs and better surrogate endpoints to accelerate pediatric drug development.